JNJ's R115777 fails two Phase IIIs

Johnson & Johnson (JNJ) said data from Phase III trials of its R115777 farnesyl transferase inhibitor in pancreatic and colorectal cancer failed to meet the primary endpoints of survival. In a double-blind international trial of 688 pancreatic patients, R115777 plus gemcitabine gave no statistically significant difference in median overall survival compared to gemcitabine alone (193 vs. 182 days, respectively, p=0.75). ...